idsmartlinkurlhttps3A2F2Fwwwalnylamcom2Fesheet52800209newsitemid2 0220803005528lanen USanchorAlnylamPharmaceuticals2CIncindex1md565b7fd906d15b70baf323ab6f b86f4afNasdaq ALNY the leading RNAi therapeutics company today announced that the APOLLOB Phase 3 study of patisiran an investigational RNAi therapeutic in development for the treatment of transthyretinmediated ATTR amyloidosis with cardiomyopathy met the primary endpoint of change from baseline in the 6Minute Walk Test 6MWT at 12 months compared to placebo pvalue 00162